Opendata, web and dolomites

CYTOPRO

Profiling of tumour cells in blood for personalized treatment of metastatic cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CYTOPRO project word cloud

Explore the words cloud of the CYTOPRO project. It provides you a very rough idea of what is the project "CYTOPRO" about.

approaching    2009    profile    superior    42    market    technologies    efficient    126bn    solution    lost    diagnosed    lives    productivity    worldwide    metastasised    trials    primary    isolate    days       5bn    detection    12    treatment    innovation    10bn    bloodstream    assays    alone    cancer    gaining    medicine    43bn    incl    exact    foothold    cheap    ctc    first    routine    10    accurate    lose    tumour    2013    larger    patients    personalised    circulating    fail    annually    expects    therapy    40    cells    7bn    citizens    isolation    customers    deaths    diagnostic    losses    prepare    breakthrough    gt    challenge    cytotrack    single    blood    form       circulate    labs    mutation    pathologists    clinicians    tool    breast    platform    patient    device    18    fast    vasculature    shed    clinical    metastatic    reduce    ctcs    biased    worth    6bn    2m    regulatory    characterisation    perfect    cell    individual    markets   

Project "CYTOPRO" data sheet

The following table provides information about the project.

Coordinator
CYTOTRACK APS 

Organization address
address: GAMMEL LUNDTOFTEVEJ 1D
city: LYNGBY
postcode: 2800
website: www.cytotrack.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.cytotrack.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTOTRACK APS DK (LYNGBY) coordinator 50˙000.00

Map

 Project objective

Challenge Up to 40% of patients diagnosed with metastasised breast cancer fail to respond to treatment. Cancer cost the EU €126bn in 2009 incl. productivity losses of €42.6bn and lost working days worth €9.43bn. 3.2m citizens in EU lose their lives to cancer each year.

Solution Circulating Tumour Cells (CTC) are cells that have shed into the vasculature from a primary tumour and circulate in the bloodstream. CytoTrack has developed a breakthrough technology that can identify and isolate metastatic cancer cells from a blood sample. It is superior to all other technologies due to a very efficient and non-biased detection principle and an integrated feature to isolate individual cells for characterisation. It is the perfect tool to be used together with new single cell characterisation assays currently being introduced on the market.

Impact The innovation will provide an effective, accurate, fast and cheap characterisation of CTCs in a single device, enabling pathologists and clinicians worldwide to deliver personalised medicine and cancer treatment targeted the exact mutation of the individual patient’s cancer form. CytoTrack expects that the innovation can reduce cancer deaths by 10%. In EU alone this would reduce the productivity loss with >€10bn per year and treatment costs with >€12.5bn.

Project This phase 1 project will investigate 1) collaboration with labs, 2) regulatory conditions for first markets, and 3) prepare for clinical trials. The overall innovation project will enable CytoTrack to be the first on the market to offer an integrated diagnostic platform for routine isolation and characterisation of metastatic cancer cells in blood, enabling personalised therapy targeting the exact profile of the cancer form.

Customers and market The CTC technology market was $3.7bn in 2013, growing 18.9% annually. The research market is a first step in gaining a strong foothold before approaching the much larger, but also more challenging, clinical market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYTOPRO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CYTOPRO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More